Pyrvinium reduces adenoma formation <i>in vivo</i>.

<p><b>A</b>. Mean number of intestinal adenomas in Pyrvinium (25 mg/kg) or vehicle treated mice. Mice were treated via oral gavage once every 48 h for 10 weeks. Intestines were removed from euthanized mice, fixed in phosphate buffered formalin and then adenomatous polyps were quantitated. Error bars represent S.E.M, n = 12. *p<0.05. <b>B</b>. Expression levels of the WNT target genes <i>AXIN2</i> and <i>LGR5</i> in the intestinal epithelium of <i>APC^min</i> mice chronically treated with vehicle control or 25 mg/Kg Pyrvinium. Total RNA from intestinal tissue sections of euthanized mice was converted to cDNA and subjected to real-time RT-PCR analysis. <b>C</b>. Mice treated with Pyrvinium for 10 weeks via oral gavage showed no significant weight loss in response to Pyrvinium treatment. <b>D</b>. Upper panels, TUNEL assays of intestinal sections from chronic Pyrvinium or vehicle treated <i>APC^min</i> mice. Intestinal tissue sections were isolated from euthanized mice embedded in paraffin and subjected to an in situ TUNEL assay using the DeadEnd colorimetric TUNEL assay (N: nucleus). Lower panels, Immunohistochemistry showing CTNNB1 expression and localization in intestinal sections from Pyrvinium and vehicle treated mice. Mice were treated for 7 days. Intestinal tissues isolated from euthanized mice were fixed using buffered formalin, paraffin embedded and subjected to immunohistochemistry using an antibody for CTNNB1 (N: nucleus). Scale = 50 µm.